cetuximab / HK2 Cancer Research Results

CET, cetuximab: Click to Expand ⟱
Features: antineoplastic drug
Cetuximab a genetically engineered monoclonal antibody (IV): inhibit tumor growth for colorectal cancer, head and neck cancer.
Cardiopulmonary arrest side effect.

Cetuximab — cetuximab is a chimeric mouse/human IgG1 monoclonal antibody directed against the extracellular domain of epidermal growth factor receptor (EGFR, ERBB1). It is a targeted antineoplastic biologic used intravenously, with established clinical use in biomarker-selected metastatic colorectal cancer and in squamous cell carcinoma of the head and neck; current practice also includes combination use with other targeted agents such as encorafenib in BRAF V600E-mutant metastatic colorectal cancer and adagrasib in previously treated KRAS G12C-mutant colorectal cancer through the partner-drug labels. Standard abbreviation: CET; trade name: Erbitux.

Primary mechanisms (ranked):

  1. EGFR extracellular-domain binding with blockade of ligand binding, receptor activation, and downstream signaling
  2. Suppression of EGFR-driven RAS-RAF-MEK-ERK and PI3K-AKT survival/proliferation signaling
  3. EGFR internalization / downregulation with reduced receptor signaling competence
  4. IgG1-mediated antibody-dependent cellular cytotoxicity against EGFR-expressing tumor cells
  5. Radiosensitization and chemosensitization in appropriate EGFR-dependent settings
  6. Secondary downstream effects including reduced proliferation and increased apoptosis; redox, autophagy, and ferroptosis effects appear context-specific rather than core class mechanisms

Bioavailability / PK relevance: Intravenous only. Systemic exposure is reliable, with distribution largely confined to vascular/interstitial space and a long terminal half-life of about 112 hours at standard dosing; weekly and every-2-week regimens are both used in current labeling regions. As a monoclonal antibody, delivery is limited by tumor perfusion, tissue penetration, EGFR expression pattern, and on-target normal-tissue binding rather than oral absorption.

In-vitro vs systemic exposure relevance: Conventional small-molecule concentration comparisons are of limited value. Cetuximab activity is target-occupancy and tissue-distribution driven, so very high in-vitro antibody concentrations may not map directly to intratumoral exposure. Mechanistic claims based mainly on combination studies or high-exposure cell culture conditions should be interpreted cautiously unless corroborated in vivo.

Clinical evidence status: Established clinical agent. Strong human evidence and randomized trial support exist in metastatic colorectal cancer and head and neck squamous cell carcinoma, but benefit is highly context- and biomarker-dependent. In colorectal cancer, activity requires RAS wild-type biology for classic anti-EGFR use; cetuximab is also a validated combination partner in newer genotype-matched regimens such as encorafenib-based BRAF V600E therapy and adagrasib-based KRAS G12C therapy.

Mechanistic relevance table

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 EGFR ligand binding and receptor activation EGFR signaling ↓ EGFR signaling ↓ in skin and epithelium Target blockade Core pharmacology. Cetuximab binds the extracellular EGFR domain and prevents ligand-driven activation.
2 RAS RAF MEK ERK and PI3K AKT survival signaling MAPK ↓; AKT survival signaling ↓ ↔ / repair signaling ↓ Antiproliferative and anti-survival effect Therapeutic leverage depends on EGFR pathway dependence; downstream RAS mutation bypasses benefit in classic mCRC use.
3 EGFR internalization and receptor downregulation EGFR surface signaling competence ↓ EGFR turnover altered Sustained receptor suppression Important supportive mechanism that can deepen pathway inhibition beyond simple ligand competition.
4 Immune cytotoxicity via Fc effector function ADCC ↑ ↔ Immune-mediated tumor cell killing Biologically relevant because cetuximab is IgG1; this distinguishes it from purely signaling-blockade interpretations.
5 Radiosensitization or chemosensitization Sensitivity to RT or selected systemic therapy ↑ Normal tissue toxicity can also ↑ Adjunct therapeutic amplification Clinically relevant in head and neck cancer and in targeted-combination CRC regimens; effect is context-dependent rather than universal.
6 Apoptosis and cell-cycle restraint Apoptosis ↑; proliferation ↓ Turnover / repair ↓ (context-dependent) Downstream phenotypic consequence Usually secondary to upstream EGFR pathway inhibition rather than a distinct primary target.
7 Redox and ferroptosis related effects ROS ↔ / ↑ (context-dependent); ferroptosis ↔ (model-dependent) ↔ Non-core context effect Nestronics currently emphasizes a 2023 combination study with 3-bromopyruvate; these effects should not be treated as central single-agent cetuximab pharmacology.
8 Clinical Translation Constraint Primary resistance and acquired bypass signaling ↑ On-target toxicity in skin and electrolyte homeostasis Limits durable benefit Key constraints include RAS-pathway escape, EGFR ectodomain resistance alterations, limited tumor penetration, infusion reactions, acneiform rash, and hypomagnesemia.


HK2, Hexokinase 2: Click to Expand ⟱
Source:
Type: enzyme
HK2 (Hexokinase 2) is an enzyme that plays a crucial role in glycolysis, the process by which cells convert glucose into energy. HK2 is a key regulatory enzyme in the glycolytic pathway, and it is primarily expressed in various tissues, including muscle, brain, and cancer cells.
HK2 has been shown to be overexpressed in many types of tumors, including breast, lung, and colon cancer. This overexpression may contribute to the development and progression of cancer by promoting glycolysis and energy production in cancer cells.
HK2 is a key regulatory enzyme in the glycolytic pathway.
HK2 plays a role in the regulation of glucose metabolism in diabetes.
HK2 is involved in the regulation of cell proliferation, apoptosis, and autophagy.

HK2 Inhibitors:
-2DG
-Curcumin
-Resveratrol
-EGCG
-Berberine
-Methyl Jasmonate (MJ)
-Honokiol
Scientific Papers found: Click to Expand⟱
5263- 3BP,  CET,    3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis
- in-vitro, CRC, DLD1 - NA, NA, HCT116
eff↑, Ferroptosis↓, TumAuto↑, Apoptosis↑, FOXO3↑, AMPKα↑, p‑Beclin-1↑, HK2↓, ATP↓, ROS↑, Dose↝, TumVol↓, TumW↓, xCT↑, GSH↓, eff↓, MDA↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↓, 1,   GSH↓, 1,   MDA↑, 1,   ROS↑, 1,   xCT↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,  

Core Metabolism/Glycolysis ⓘ

HK2↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Ferroptosis↓, 1,  

Kinase & Signal Transduction ⓘ

AMPKα↑, 1,  

Autophagy & Lysosomes ⓘ

p‑Beclin-1↑, 1,   TumAuto↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

FOXO3↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↓, 1,   eff↑, 1,  

Functional Outcomes ⓘ

TumVol↓, 1,   TumW↓, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: HK2, Hexokinase 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:5  Target#:773  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page